A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Varlilumab (Primary)
Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Liver cancer
Focus Therapeutic Use

19 Jul 2024 Planned End Date changed from 1 Sep 2024 to 17 Jul 2025.
04 Jun 2024 Primary endpoint has not been met. (Overall response rate (ORR))
04 Jun 2024 Interim results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com